BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update

About this update from Bioporto A/s

[{"type":"image","alt":"BioPorto A/S","displaySize":"","headline":null,"caption":"BioPorto A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XFhYiV2fxrmNbtDA3N3v_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8","width":300,"height":55}},"lazy":false},{"type":"text","content":"February 5, 2026Announcement no. 1","length":35,"tagName":"p"},{"type":"text","content":"BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update","length":113,"tagName":"p"},{"type":"text","content":"COPENHAGEN, DENMARK, February 5, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), today announced Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a business update. ","length":237,"tagName":"p"},{"type":"text","content":"A strong quarter to close out the year - Preliminary Financial Figures for the Fourth Quarter of 2025 and Fiscal Year 2025","length":122,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In the fourth quarter of 2025, BioPorto’s revenue amounted to DKK 11.6 million, corresponding to an increase of 47% versus prior year, and a 52% increase at constant exchange rates. The very strong growth was primarily driven by NGAL (Research Use Only (RUO)) in the US and revenue from strategic distributors. Revenues from strategic distributors can be lumpy, and it remains premature to assume a steady quarterly cadence of this revenue stream.","length":447,"tagName":"p"}]},{"val":[{"type":"text","content":"Revenue for the 2025 financial year amounted to DKK 40.3 million, compared to DKK 36.2 million in the previous year, representing a revenue growth of 11%, and at constant exchange rate a growth of 13%. The growth was strongly driven by NGAL RUO in the U.S. growing 25% to DKK 18.4 million, and 29% at constant exchange rates. Further, revenues from strategic distributors of NGAL contributed by additional DKK 4.3 million. Total NGAL share of the total revenue amounted to 70%. The preliminary revenue for the 2025 financial year is within the latest disclosed guidance of DKK 40-45...

More updates from Bioporto A/s